Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the (a) adequacy of the eligibility criteria for (i) free covid-19 vaccinations and (ii) access to covid-19 antiviral treatments for people with lung cancer and chronic obstructive pulmonary disease and (b) consistency of eligibility criteria used by general practices, community pharmacies and NHS 111 in England.

Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)

The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness, resulting in hospitalisations and deaths, arising from COVID-19.

The JCVI has advised that population immunity to COVID-19 has been increasing due to a combination of naturally acquired immunity following recovery from infection and vaccine-derived immunity. COVID-19 is now a relatively mild disease for most people, though it can still be unpleasant, with rates of hospitalisation and death from COVID-19 having reduced significantly since COVID-19 first emerged.

The focus of the JCVI’s advised programme has therefore moved towards targeted vaccination of the two groups who continue to be at higher risk of serious disease, including mortality. These are the oldest adults and individuals who are immunosuppressed. The Government has accepted the JCVI’s advice for autumn 2025 and in line with the advice, a COVID-19 vaccination is being offered to the following groups:

• adults aged 75 years old and over;
• residents in care homes for older adults; and
• individuals aged six months old and over who are immunosuppressed.

The COVID-19 chapter of the UK Health Security Agency Green Book on immunisation against infectious disease sets out guidance on the eligibility criteria above. This is signposted to all providers to ensure consistency. As for all vaccines, the JCVI keeps the evidence under regular review.

The National Institute for Health and Care Excellence has published guidance that recommends several antivirals for the treatment of COVID-19, both in the community and for patients in hospital. This guidance sets out the eligibility criteria and ensures that patients who are at the highest risk of developing severe disease from COVID-19 have access to clinically- and cost-effective treatments.

Thanking postal workers

Found: Watch the meeting Members present: Ruth Cadbury (Chair); Steff Aquarone; Dr Scott Arthur; Jacob Collier

Found: Watch the meeting Members present: Ruth Cadbury (Chair); Steff Aquarone; Dr Scott Arthur; Jacob Collier